Drug Approval | April 14, 2026
FDA fast-tracks Daiichi Sankyo & Merck lung cancer drug review
The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis
The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis
MoU to deploy Qure.ai’s chest X-ray solution across 20 government facilities aims to improve early detection in urban and rural populations
The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611
Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
The drug’s safety profile in LIBRETTO-432 aligned with previous selpercatinib studies, showing no unexpected concerns
This approval builds on the recent transformation RYBREVANT FASPRO brought to lung cancer care
Dr Adams’ lab recently uncovered a novel cellular detoxification pathway driving Cisplatin resistance in NSCLC
The trial, which compared Retevmo to placebo, met its primary endpoint with a “highly statistically significant and clinically meaningful improvement” in investigator-assessed EFS for patients with stage II–IIIA disease
Sevabertinib is an oral, reversible tyrosine kinase inhibitor (TKI) that directly targets HER2 mutations
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
